Skip to main content

Lung Infection

1
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Aridis Pharmaceuticals
1 program
1
AR-301Phase 31 trial
Active Trials
NCT03816956Completed174Est. Oct 2022
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
Fecal suspensionN/A1 trial
Active Trials
NCT06970262Recruiting150Est. Dec 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Aridis PharmaceuticalsAR-301
UNION therapeuticsFecal suspension

Clinical Trials (2)

Total enrollment: 324 patients across 2 trials

Adjunctive Therapy to Antibiotics in the Treatment of S. Aureus Ventilator-Associated Pneumonia With AR-301

Start: May 2019Est. completion: Oct 2022174 patients
Phase 3Completed

FMT for Lung and Associated-organ Rescue Efficacy in ARDS Patients

Start: Apr 2026Est. completion: Dec 2026150 patients
N/ARecruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 324 patients
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.